Ligand Pharmaceuticals Incorporated provided earnings guidance for the year 2024. For the year, the company expects total revenue of $130 million to $142 million, comprised of $90 million to $95 million from royalties, $25 million to $27 million from sales of Captisol and $15 million to $20 million from contract revenue.